Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 12, 2019 08:30 ET | Source: Mateon Therapeutics

Oncotelic Appoints Four Eminent Physician-Scientists Internationally Recognized for their Work in Oncology and Immunology to Newly Established Medical Advisory Board

AGOURA HILLS, Calif., June 12, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic”), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB: MATN) dedicated to development of innovative...
June 10, 2019 08:30 ET | Source: Mateon Therapeutics

Mateon and Oncotelic Report on Continuing Integration of the two Businesses

-Relocation of Corporate Headquarters -Introduction of Amit Shah as incoming CFO -Presentation of Integrated Pipeline at BIO2019 AGOURA HILLS, Calif., June 10, 2019 ...
May 15, 2019 09:39 ET | Source: Mateon Therapeutics

Mateon Reports First Quarter 2019 Financial Results

SOUTH SAN FRANCISCO, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...
April 25, 2019 06:35 ET | Source: Mateon Therapeutics

Mateon and Oncotelic Complete Their Merger and Create a New Immuno-Oncology Company with a Late-Stage Clinical Asset Against Cancer and a Promising Product Pipeline

-Merger creates a publicly-traded clinical stage immuno-oncology company developing treatments for advanced cancers including aggressive brain tumors, pancreatic cancer, and melanoma -Phase 2...
April 18, 2019 06:01 ET | Source: Mateon Therapeutics

Mateon Enters into Merger Agreement with Oncotelic

SOUTH SAN FRANCISCO, Calif. and AGOURA HILLS, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) and Oncotelic Inc., a privately-held, late clinical-stage cancer...
November 14, 2018 08:45 ET | Source: Mateon Therapeutics

Mateon Therapeutics Reports Third Quarter 2018 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...
August 30, 2018 09:00 ET | Source: Mateon Therapeutics

Mateon Therapeutics to Present at the Rodman & Renshaw Investor Conference on September 6, 2018

SOUTH SAN FRANCISCO, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing drugs for the treatment of orphan oncology indications,...
August 17, 2018 08:50 ET | Source: Mateon Therapeutics

Mateon Therapeutics Receives Notice of Partial Clinical Hold for OX1222 Study

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...
August 14, 2018 16:25 ET | Source: Mateon Therapeutics

Mateon Therapeutics Reports Second Quarter 2018 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...
May 14, 2018 07:45 ET | Source: Mateon Therapeutics

Mateon Therapeutics Reports First Quarter 2018 Financial Results

SOUTH SAN FRANCISCO, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan...